News We’re Watching: Trial Lab Warning Letters, Novartis Adds US Plants, Abbott Launches OTC Lingo Glucose Monitor

This week, two device testing labs in China landed FDA warning letters; refunds for 1Health.io clients; FDA AR/VR product list expands. 

"News We're Watching" Feature Image
• Source: Medtech Insight

Two Chinese nonclinical laboratory testing facilities have been issued FDA warning letters related to laboratory oversight failures and animal care violations.

The letters went to Mid-Link Testing Company Ltd. in Tianjin, China, and Sanitation & Environmental Technology Institute of Soochow University Ltd

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Approvals

More from News We're Watching